Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
The group’s point-of-care Car-T push looks to have stalled.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.